DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aptiom (Eslicarbazepine Acetate) - Summary



APTIOM (eslicarbazepine acetate) is a dibenz[b,f]azepine-5-carboxamide derivative.

APTIOM (eslicarbazepine acetate) is indicated as adjunctive treatment of partial-onset seizures.
See all Aptiom indications & dosage >>


Published Studies Related to Aptiom (Eslicarbazepine)

Evaluation of Eslicarbazepine acetate on cardiac repolarization in a thorough QT/QTc study. [2012]
This study investigated the effect of eslicarbazepine acetate (ESL) on cardiac repolarization in healthy adult volunteers. A randomized, placebo/active-controlled, 4-period crossover study was conducted in 67 participants...

Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. [2011]
CONCLUSIONS: Eslicarbazepine acetate reduces seizure frequency when used

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. [2010]
The results of two single-blind studies conducted to evaluate the cognitive and psychomotor effects of eslicarbazepine acetate and oxcarbazepine following single and repeated administration in healthy volunteers are reported... The incidence of adverse events was lower with eslicarbazepine acetate than with oxcarbazepine.

Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. [2007]
partial epilepsy... CONCLUSION: Eslicarbazepine acetate was efficacious and well tolerated as an

more studies >>

Clinical Trials Related to Aptiom (Eslicarbazepine)

Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder [Completed]
This was an extension study consisting of 2 parts. In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks. Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily. Patients stable in remission continued double-blind therapy until approximately 6 months after the last patient entered Part II.

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin [Completed]

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers [Completed]
Single centre, double-blind, randomised, placebo-controlled study of two dosage regimens of

BIA 2-093 - 1800 mg (Group 1) and 2400 mg (Group 2) - in two groups of healthy male


Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers [Completed]

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures [Active, not recruiting]
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures

more trials >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017